Your patient has a lower GI bleed on ASA—Do you resume antiplatelet therapy?Study suggests balance favours resumption, to reduce cardiovascular risk Bleeding risk increased with dabigatran-statin comboStudy of Ontario seniors suggests caution needed with simvastatin and lovastatin Clinical Feature: Update on managing dyslipidemia A review of the updated Canadian Cardiovascular Society guidelines for dyslipidemia management. Edoxaban (Lixiana) approved in Canada Fourth direct-acting oral anticoagulant expected to reach Canadian market in early 2017. Relative cardiovascular safety of celecoxib confirmed COX-2 inhibitor is ‘non-inferior’ to ibuprofen and naproxen, trial shows Anticoagulant antidote works Beyond statins: What you need to know about alternative lipid-lowering agents Wrist-worn heart monitors not always accurate Validation ‘imperative’ for serious clinical use, researchers say Case Report: A patient with familial dyslipidemia fails to respond to statins Got patients with a-fib? You need to read this Recent studies evaluate biomarkers for risk assessment and compare oral anticoagulants First Previous 42 43 44 45 46 Next Last
